newsfilter
← Latest News
GlobeNewswire·

Genocea Provides Second Quarter 2021 Corporate Update

GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues GEN-009 neoantigen vaccine candidate shows promising long-term clinical results Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWS